Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFRmutant Advanced NSCLC Beyond Limited Progression on Osimertinib

Author(s): Meifang Li, Cheng Lin, Jinghui Lin, Shijie Chen, Lihong Weng and Zhiyong He*

Volume 23, Issue 19, 2023

Published on: 20 September, 2023

Page: [2095 - 2101] Pages: 7

DOI: 10.2174/1871520623666230803142758

open access plus

Abstract

Background: Treatment options for advanced non-small-cell lung cancer (NSCLC) after osimertinib failure are limited, and osimertinib continuation is recommended for selected patients. Metronomic oral vinorelbine is an effective treatment with less toxicity for advanced NSCLC.

Objective: The objective of the study was to investigate the effects of osimertinib plus metronomic oral vinorelbine on epidermal growth factor receptor (EGFR)-mutant advanced NSCLC beyond limited progression on osimertinib.

Methods: We have reviewed the medical records of 28 patients with EGFR-mutant advanced NSCLC who had received osimertinib continuation plus metronomic oral vinorelbine beyond limited progression on osimertinib. We also evaluated the clinicopathological characteristics of enrolled patients, as well as the efficacy and toxicity of the treatment.

Results: After a median follow-up period of 14.1 months, 57.1% (16/28) of cases showed NSCLC progression. The median progression-free survival (PFS) period under osimertinib plus metronomic oral vinorelbine was 9.4 months (95% confidence interval, 1.562–17.238 months), with a disease control rate of 89.3% and objective response rate of 17.9%. PFS did not differ between patients who had previously received osimertinib as first- (n = 16) and second-line (n = 12) therapy (median, 11.4 and 4.7 months, P = 0.391). In addition, the median PFS duration did not differ according to the efficacy (PFS2 ≥ 6 months vs. <6 months) of previous osimertinib monotherapy (median, 5.8 and 9.4 months, P = 0.677).

Conclusions: Osimertinib continuation in conjunction with metronomic oral vinorelbine may enable overcoming TKI resistance and prolong the survival of patients with EGFR-mutant advanced NSCLC beyond limited progression on osimertinib treatment.

Keywords: EGFR, non-small cell lung cancer, osimertinib, metronomic chemotherapy, limited progression, TKI resistance.

« Previous Next »
Graphical Abstract

[1]
Soria, J.C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B.C.; Cheng, Y.; Cho, E.K.; Voon, P.J.; Planchard, D.; Su, W.C.; Gray, J.E.; Lee, S.M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S.S. Osimertinib in untreated EGFR -mutated advanced non–small-cell lung cancer. N. Engl. J. Med., 2018, 378(2), 113-125.
[http://dx.doi.org/10.1056/NEJMoa1713137] [PMID: 29151359]
[2]
Goss, G.; Tsai, C.M.; Shepherd, F.A.; Bazhenova, L.; Lee, J.S.; Chang, G.C.; Crino, L.; Satouchi, M.; Chu, Q.; Hida, T.; Han, J.Y.; Juan, O.; Dunphy, F.; Nishio, M.; Kang, J.H.; Majem, M.; Mann, H.; Cantarini, M.; Ghiorghiu, S.; Mitsudomi, T. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol., 2016, 17(12), 1643-1652.
[http://dx.doi.org/10.1016/S1470-2045(16)30508-3] [PMID: 27751847]
[3]
(a) Wang, S.; Tsui, S.T.; Liu, C.; Song, Y.; Liu, D. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J. Hematol. Oncol., 2020, 9(1), 1-5.
[http://dx.doi.org/10.1186/s13045-016-0290-1];
(b) Oxnard, G.; Hu, Y.; Mileham, K.; Husain, H.; Costa, D.; Tracy, P.; Feeney, N. Assessment of resistance mechanisms and clinical implications in patients WithEGFRT790M–Positive lung cancer and acquired resistance to osimertinib. JAMA Oncology., 2018, 4(11), 1527.
[http://dx.doi.org/10.1001/jamaoncol.2018.2969];
(c) Leonetti, A.; Sharma, S.; Minari, R.; Perego, P.; Giovannetti, E.; Tiseo, M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer, 2019, 121(9), 725-727.
[http://dx.doi.org/10.1038/s41416-019-0573-8];
(d) Piper-Vallillo, A.J.; Sequist, L.Y.; Piotrowska, Z. Emerging treatment paradigms for EGFR-Mutant lung cancers progressing on osimertinib: A review. J. Clin. Oncol., 2020, JCO1903123.
[http://dx.doi.org/10.1001/jamaoncol.2018.2969]
[4]
Kim, J.Y.; Kim, Y.M. Tumor endothelial cells as a potential target of metronomic chemotherapy. Arch. Pharm. Res., 2019, 42(1), 1-13.
[http://dx.doi.org/10.1007/s12272-018-01102-z] [PMID: 30604201]
[5]
Klement, G.; Baruchel, S.; Rak, J.; Man, S.; Clark, K.; Hicklin, D.J.; Bohlen, P.; Kerbel, R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest., 2000, 105(8), R15-R24.
[http://dx.doi.org/10.1172/JCI8829] [PMID: 10772661]
[6]
Camerini, A.; Banna, G.L.; Cinieri, S.; Pezzuto, A.; Mencoboni, M.; Rosetti, F.; Figueiredo, A.; Rizzo, P.; Ricci, A.; Langenhoven, L.; Santo, A.; Addeo, A.; Amoroso, D.; Barata, F. Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: A multi-center international retrospective analysis. Clin. Transl. Oncol., 2019, 21(6), 790-795.
[http://dx.doi.org/10.1007/s12094-018-1989-y] [PMID: 30448956]
[7]
Saito, H.; Fukuhara, T.; Furuya, N.; Watanabe, K.; Sugawara, S.; Iwasawa, S.; Tsunezuka, Y.; Yamaguchi, O.; Okada, M.; Yoshimori, K.; Nakachi, I.; Gemma, A.; Azuma, K.; Kurimoto, F.; Tsubata, Y.; Fujita, Y.; Nagashima, H.; Asai, G.; Watanabe, S.; Miyazaki, M.; Hagiwara, K.; Nukiwa, T.; Morita, S.; Kobayashi, K.; Maemondo, M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol., 2019, 20(5), 625-635.
[http://dx.doi.org/10.1016/S1470-2045(19)30035-X] [PMID: 30975627]
[8]
Hosomi, Y.; Morita, S.; Sugawara, S.; Kato, T.; Fukuhara, T.; Gemma, A.; Takahashi, K.; Fujita, Y.; Harada, T.; Minato, K.; Takamura, K.; Hagiwara, K.; Kobayashi, K.; Nukiwa, T.; Inoue, A. Gefitinib alone versus gefitinib plus chemotherapy for non–small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J. Clin. Oncol., 2020, 38(2), 115-123.
[http://dx.doi.org/10.1200/JCO.19.01488] [PMID: 31682542]
[9]
Passaro, A.; Leighl, N.; Blackhall, F.; Popat, S.; Kerr, K.; Ahn, M.J.; Arcila, M.E.; Arrieta, O.; Planchard, D.; de Marinis, F.; Dingemans, A.M.; Dziadziuszko, R.; Faivre-Finn, C.; Feldman, J.; Felip, E.; Curigliano, G.; Herbst, R.; Jänne, P.A.; John, T.; Mitsudomi, T.; Mok, T.; Normanno, N.; Paz-Ares, L.; Ramalingam, S.; Sequist, L.; Vansteenkiste, J.; Wistuba, I.I.; Wolf, J.; Wu, Y.L.; Yang, S.R.; Yang, J.C.H.; Yatabe, Y.; Pentheroudakis, G.; Peters, S. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol., 2022, 33(5), 466-487.
[http://dx.doi.org/10.1016/j.annonc.2022.02.003] [PMID: 35176458]
[10]
(a) Sequist, L.V.; Han, J.Y.; Ahn, M.J.; Cho, B.C.; Yu, H.; Kim, S.W.; Yang, J.C.; Lee, J.S.; Su, W.C.; Kowalski, D. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol., 2020, 21(3), 373-386.
[http://dx.doi.org/10.1016/S1470-2045(19)30785-5];
(b) Passaro, A.; Janne, P.A.; Mok, T.; Peters, S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat. Cancer., 2020, 2(4), 377-391.
[http://dx.doi.org/10.1038/s43018-021-00195-8]
[11]
Mok, T.S.K.; Kim, S.W.; Wu, Y.L.; Nakagawa, K.; Yang, J.J.; Ahn, M.J.; Wang, J.; Yang, J.C.H.; Lu, Y.; Atagi, S.; Ponce, S.; Shi, X.; Rukazenkov, Y.; Haddad, V.; Thress, K.S.; Soria, J.C. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation–positive non–small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses. J. Clin. Oncol., 2017, 35(36), 4027-4034.
[http://dx.doi.org/10.1200/JCO.2017.73.9250] [PMID: 28968167]
[12]
Yang, J.J.; Chen, H.J.; Yan, H.H.; Zhang, X.C.; Zhou, Q.; Su, J.; Wang, Z.; Xu, C.R.; Huang, Y.S.; Wang, B.C.; Yang, X.N.; Zhong, W.Z.; Nie, Q.; Liao, R.Q.; Jiang, B.Y.; Dong, S.; Wu, Y.L. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer, 2013, 79(1), 33-39.
[http://dx.doi.org/10.1016/j.lungcan.2012.09.016] [PMID: 23079155]
[13]
Le, X.; Puri, S.; Negrao, M.V.; Nilsson, M.B.; Robichaux, J.; Boyle, T.; Hicks, J.K.; Lovinger, K.L.; Roarty, E.; Rinsurongkawong, W.; Tang, M.; Sun, H.; Elamin, Y.; Lacerda, L.C.; Lewis, J.; Roth, J.A.; Swisher, S.G.; Lee, J.J.; William, W.N., Jr; Glisson, B.S.; Zhang, J.; Papadimitrakopoulou, V.A.; Gray, J.E.; Heymach, J.V. Landscape of EGFR-Dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR -mutant NSCLC. Clin. Cancer Res., 2018, 24(24), 6195-6203.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-1542] [PMID: 30228210]
[14]
(a) Nishie, K.; Kawaguchi, T.; Tamiya, A.; Mimori, T.; Takeuchi, N.; Matsuda, Y.; Omachi, N.; Asami, K.; Okishio, K.; Atagi, S. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: A retrospective analysis for Japanese patients with activating EGFR mutations. J. Thorac. Oncol., 2012, 7(11), 1722-1727.
[http://dx.doi.org/10.1097/JTO.0b013e31826913f7];
(b) Maruyama, R.; Wataya, H.; Seto, T.; Ichinose, Y. Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer. Anticancer Res., 2009, 29(10), 4217-4221.;
(c) Asami, K.; Okuma, T.; Hirashima, T.; Kawahara, M. Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations. Lung Cancer, 2013, 79(3), 276-282.
[15]
Gomez, D.R.; Blumenschein, G.R., Jr; Lee, J.J.; Hernandez, M.; Ye, R.; Camidge, D.R.; Doebele, R.C.; Skoulidis, F.; Gaspar, L.E.; Gibbons, D.L.; Karam, J.A.; Kavanagh, B.D.; Tang, C.; Komaki, R.; Louie, A.V.; Palma, D.A.; Tsao, A.S.; Sepesi, B.; William, W.N.; Zhang, J.; Shi, Q.; Wang, X.S.; Swisher, S.G.; Heymach, J.V. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study. Lancet Oncol., 2016, 17(12), 1672-1682.
[http://dx.doi.org/10.1016/S1470-2045(16)30532-0] [PMID: 27789196]
[16]
(a) Kerbel, R.S.; Kamen, B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer, 2004, 4(6), 423-436.
[http://dx.doi.org/10.1038/nrc1369];
(b) Biziota, E.; Mavroeidis, L.; Hatzimichael, E.; Pappas, P. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Lett., 2017, 400, 243-251.
[http://dx.doi.org/10.1016/j.canlet.2016.12.018]
[17]
(a) Kareva, I.; Waxman, D.J.; Lakka, K.G. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett., 2015, 358(2), 100-106.
[http://dx.doi.org/10.1016/j.canlet.2014.12.039];
(b) Natale, G.; Bocci, G. Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data. Cancer Lett., 2018, 432, 28-37.
[http://dx.doi.org/10.1016/j.canlet.2018.06.002]
[18]
Nakagawa, K.; Garon, E.B.; Seto, T.; Nishio, M.; Ponce Aix, S.; Paz-Ares, L.; Chiu, C.H.; Park, K.; Novello, S.; Nadal, E.; Imamura, F.; Yoh, K.; Shih, J.Y.; Au, K.H.; Moro-Sibilot, D.; Enatsu, S.; Zimmermann, A.; Frimodt-Moller, B.; Visseren-Grul, C.; Reck, M.; Chu, Q.; Cortot, A.; Pujol, J-L.; Moro-Sibilot, D.; Fabre, E.; Lamour, C.; Bischoff, H.; Kollmeier, J.; Reck, M.; Kimmich, M.; Engel-Riedel, W.; Hammerschmidt, S.; Schütte, W.; Syrigos, K.; Ho, J.C.M.; Au, K-H.; Novello, S.; Ardizzoni, A.; Pasello, G.; Gregorc, V.; Del Conte, A.; Galetta, D.; Takahashi, T.; Nakagawa, K.; Nishio, M.; Yoh, K.; Seto, T.; Imamura, F.; Kumagai, T.; Hotta, K.; Goto, Y.; Hosomi, Y.; Sakai, H.; Takiguchi, Y.; Kim, Y.H.; Kurata, T.; Yamaguchi, H.; Daga, H.; Okamoto, I.; Satouchi, M.; Ikeda, S.; Kasahara, K.; Atagi, S.; Azuma, K.; Kumagai, T.; Aoe, K.; Kumagai, T.; Aoe, K.; Horio, Y.; Yamamoto, N.; Tanaka, H.; Watanabe, S.; Nogami, N.; Ozaki, T.; Koyama, R.; Hirashima, T.; Kaneda, H.; Tomii, K.; Fujita, Y.; Seike, M.; Nishimura, N.; Kato, T.; Ichiki, M.; Saka, H.; Hirano, K.; Nakahara, Y.; Sugawara, S.; Park, K.; Kim, S-W.; Min, Y.J.; Lee, H.W.; Kang, J-H.; An, H.J.; Lee, K.H.; Kim, J-S.; Lee, G-W.; Lee, S.Y.; Alexandru, A.; Udrea, A.A.; Juan-Vidal, Ó.; Nadal-Alforja, E.; Gil-Bazo, I.; Ponce-Aix, S.; Paz-Ares, L.; Rubio-Viqueira, B.; Alonso, G, M. ; Felip Font, E.; Fuentes P, J.; Coves Sarto, J.; Lin, M-C.; Su, W-C.; Hsia, T-C.; Chang, G-C.; Wei, Y-F.; Chiu, C-H.; Shih, J-Y.; Su, J.; Cicin, I.; Goksel, T.; Harputluoglu, H.; Ozyilkan, O.; Henning, I.; Popat, S.; Hatcher, O.; Mileham, K.; Acoba, J.; Garon, E.; Jung, G.; Raj, M.; Martin, W.; Dakhil, S. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2019, 20(12), 1655-1669.
[http://dx.doi.org/10.1016/S1470-2045(19)30634-5] [PMID: 31591063]
[19]
Orlandi, P.; Di Desidero, T.; Salvia, G.; Muscatello, B.; Francia, G.; Bocci, G. Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors. Biochem. Pharmacol., 2018, 152, 327-337.
[http://dx.doi.org/10.1016/j.bcp.2018.04.011] [PMID: 29660315]
[20]
Gu, J.; Yao, W.; Shi, P.; Zhang, G.; Owonikoko, T.K.; Ramalingam, S.S.; Sun, S.Y. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers. Cancer, 2020, 126(16), 3788-3799.
[http://dx.doi.org/10.1002/cncr.32996] [PMID: 32497272]

Rights & Permissions Print Cite
Article Metrics
33
2
World No Tabaco Day
© 2024 Bentham Science Publishers | Privacy Policy